Kymera Therapeutics' KT-413 Shows Encouraging Preclinical Anti-Cancer Activity

Kymera Therapeutics Inc KYMR has announced new preclinical data on its IRAKIMiD degrader KT-413's potential as both a monotherapy and in combination with other anticancer agents.
The data were featured at the Annual International Conference on Malignant Lymphoma (ICML) virtual meeting.
KT-413 is currently in preclinical development, and Kymera plans to submit an Investigational New Drug Application to the FDA in the second half of 2021.
In the mouse xenograft model, intermittent dosing of KT-413 in vivo induced deep and sustained antitumor activity, including complete or partial regressions.
The response was found to be superior to the clinically active IRAK4 kinase inhibitor Curis Inc's CRIS CA-4948 or the latest generation IMiD CC-220 from Bristol Myers' BMS Celgene.
KT-413 showed potent tumor growth inhibition (87%-100%) in multiple MYD88-mutant diffuse large B-cell lymphoma patient-derived xenograft in vivo models.
The data also demonstrated KT-413's supra-additive activity in combination with rituximab, BTK inhibitors, and BCL2 inhibitors, supporting the clinical potential for KT-413 as a combination therapy in MYD88-mutant DLBCL and other MYD88-mutant B cell lymphomas.
Price Action: KYMR shares are up 0.72% at $47.69 on the last check Monday.